An engaging mix of new and returning programming is planned for ACR Convergence in Washington, D.C. “ACR Convergence is unique because of the blend of high-quality science, updates on advances in clinical care and networking opportunities to advance the field of rheumatology,” says Annual Meeting Planning Committee (AMPC) Chair Gregory C. Gardner, MD, MACP. “We…
During the height of the pandemic four years ago, I took every precaution to avoid, or at the very least, delay contracting COVID-19. I religiously wore a mask in all public settings, I washed my hands so frequently that my skin became dry and cracked, and I studiously maintained a six-foot distance from others. But…
In this ACR Convergence 2023 session, experts offered guidance on a selection of diagnostic & treatment challenges rheumatologists may encounter.
In 59,970 twins aged 35 years or older, Magnusson et al. compared how much genetics contributes to osteoarthritis (OA) with the genetic contribution to other rheumatic/musculoskeletal diseases (RMDs) in the same population, while exploring the role of shared genetics in OA and other RMDs. The researchers used data from the Swedish Twin Registry, in addition to the Swedish National Patient Register. They concluded that the heritability (i.e., the total genetic contribution to a trait) of OA is relatively large compared with other rheumatic musculoskeletal diseases.
What Are the Therapeutic Alternatives When a Janus Kinase Inhibitor Fails to Work? SAN DIEGO—Treatment alternatives after Janus kinase (JAK) inhibitor failure in real-life conditions were analyzed and presented at ACR Convergence 2023 by Pablo Francisco Muñoz Martínez, a rheumatologist at the Hospital Universitario y Politécnico La Fe, Sagunto, Spain.1 JAK inhibitors are newer, targeted…
SAN DIEGO—During ACR Convergence 2023 in November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP Merit Awards and ARP Master class, recognizing outstanding contributions to the field of rheumatology. The…
An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.
SAN DIEGO—Gout has sometimes been called the disease of kings, not only because of the fact that purine-rich foods were long affordable only to wealthier individuals, but also because the disease has been around since the monarchies that existed centuries ago. However, with groundbreaking research leading to a better understanding of gout, we can now…
SAN DIEGO—At ACR Convergence 2023, Philip Seo, MD, MHS, presented an overview of clinical updates in rheumatology from the past year.